IOL Chem and Pharma Q1 FY27 earnings call

What moved the numbers, as management explained it

• Paracetamol prices softened from peak over the last six months; other API prices stabilized; Ibu prices more or less unchanged, hovering at the same level.
• Ibuprofen existing facility at 90-95% utilization, leaving limited headroom and driving the 6,000 MTPA expansion decision.
• Full backward integration on Ibu and Paracetamol controls raw material price fluctuation up to maximum extent; long-term contracts include price-adjustment clauses.
• ~30% of ~₹500 cr new capex already incurred; balance to spread across FY27 and FY28; funded through internal accruals with no EBIT impact expected.
• FY27 EBITDA margin guidance 'more or less the same' as prior 14-14.5%.

The numbers management led with

• Total capex announced: ~INR500 crores across three growth initiatives
• Ibuprofen capex: ~INR350 crores for Ibuprofen capacity expansion
• Ibuprofen capacity expansion: +6,000 MTPA to take total capacity to 18,000 MTPA

Guidance on this call

What changed since the Fri 22 May 2026 call

Guided on earlier calls, and what was filed

Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.

By business

Balance sheet, capex and funding

• Total ~₹500 cr proposed investment across three initiatives: ~₹350 cr Ibu, ~₹110 cr CDMO, balance for specialty chemicals tolling unit.
• ~30% of ~₹500 cr capex already incurred; balance to be deployed across FY27 and FY28.
• All three initiatives to be funded entirely through internal accruals; no debt or equity dilution.
• EBIT not expected to be impacted by capex deployment given internal accruals funding.
• Separate greenfield project at 100-acre site (25-30 km away): INR1,200-1,400 cr over 4-5 years; most regulatory approvals secured, awaiting balance before full construction.

The industry, as management sees it

Ibuprofen is a stable-growth commodity with global demand growth of 3-4% annually; the segment currently shows stable pricing even as some input materials have eased from peak levels. Geopolitical/Middle East-related feedstock price increases have largely been neutralised through price-adjustment clauses and full backward integration.

Risks management named

• Ibuprofen pricing has not softened despite raw-material easing, raising margin sensitivity
• Asset-turn estimates (1.75x-2x) are indicative and depend on geography, customer mix and cycles
• CDMO ramp is gated by customer development cycles and regulatory approvals beyond EU GMP
• Geopolitical/feedstock price swings historically pressure margins (now neutralised)
• Greenfield capex of INR1,200-1,400 crores pending full regulatory approvals

Not answered directly

• CDMO segment-specific margin numbers
• Long-term 3-5 year CDMO vision / size of opportunity
• Exact percentage of incremental Ibuprofen capacity backed by existing customer relationships

Asked for a number, answered without one

• CDMO segment margins: Management said margins are 'sort of better than the margin available on the API' but said it is 'very early to discuss on the exact margin numbers'.
• Long-term CDMO business vision: Management said it would be 'early to discuss post 3-4 years of this line' and will share details once optimum utilization is achieved and customer response is known.
• Ibu incremental capacity supported by existing customers: Management said it is 'not in a position to share the correct number' for the percentage supported by existing versus new customers.

Every question, with its answer

1. 1. Ibuprofen capacity & asset turns

   Disha, Sapphire Capital

   Question. On the ~INR350 crore Ibuprofen capacity, when does it come online and what asset turns are we looking at?

   Answer, Abhay Raj Singh, Sr. VP & Company Secretary. Commercialisation by December 2027. Asset turn is about 1.75x of investment at peak utilisation. Generally, pharma investments see 1.75x to 2x top line, but the actual figure depends on geography, customer mix, contract type and market cycles.

   Follow-up. How quickly will we be able to utilise it? By FY29, what utilisation are we targeting?

   Answer. Q3 FY28 it will be commercialised; in FY28 around 25% utilisation can be reached; optimum utilisation more than 80% in FY28-FY29. This is for Ibu only.

2. 2. CDMO business outlook & margins

   Disha, Sapphire Capital

   Question. For the CDMO business, what sort of contribution can we expect this year and next, and what margins?

   Answer, Abhay Kumar Singh, Sr. VP & Company Secretary. Commercialising in Q3 FY27. Numbers depend on APIs going into this segment but average is around 1x-1.25x at ~90% utilisation. Kushal Rana added that ramp depends on customer development and regulatory approval cycle. Pardeep Khanna confirmed optimal utilisation expected in 18-24 months. Margin numbers described as better than API margins but specific numbers said to be too early to discuss.

   Not answered directly.

3. 3. Pricing environment for Paracetamol and APIs

   Disha, Sapphire Capital

   Question. On the current pricing environment — Paracetamol prices going up and chemicals skyrocketing due to war. What's the current situation and will these prices sustain?

   Answer, Abhay Raj Singh, Sr. VP & Company Secretary. Paracetamol prices have softened down from their peak over the last six months and are not going upward. Most APIs we are in are either stabilised or not going upward. Paracetamol specifically has come down from peak.

4. 4. FY27/FY28 revenue guidance

   Disha, Sapphire Capital

   Question. For FY28, any color on what revenue and margins we are targeting given capex coming online?

   Answer, Abhay Raj Singh, Sr. VP & Company Secretary. This capex will not be material within the current financial year. Maintaining FY27 guidance in line with the last call at 15-20%. FY28 also won't see full commercialisation; full utilisation in FY28-29. At the top level, 25-30% incremental in top line after completion of all three full-fledged projects.

5. 5. Ibuprofen demand drivers

   Surabhi, NV Alpha

   Question. On Ibuprofen expansion — capacity is being raised by 50% despite being a stable-growth commodity. Where is the demand coming from — competitor plant shutdown, transfer, or new demand?

   Answer, Kushal Kumar Rana, Director Works. Demand is coming from development with domestic and international customers; current capacity exhausted up to 90-95% utilisation; and additional volumes are being planned for the CDMO business. Considering all factors, the capacity is being increased.

   Follow-up. Is the European formulation business largely existing products using captive API? And how were these European customers cracked — did they approach IOL or did IOL diversify?

   Answer. Customers came back asking why not supply bulk tablets instead of APIs; mutual agreement led to this arrangement. Yes, formulations are existing products (Pantoprazole, Clopidogrel, Ibuprofen, Metformin) with captive API usage.

6. 6. CDMO contract tenure

   Surabhi, NV Alpha

   Question. What is the contract tenure or soft commitments in the formulation business?

   Answer, Abhay Raj Singh, Sr. VP & Company Secretary. Discussions with various customers; similar contract terms as API contracts ranging 3 to 5 years with escalation clauses and other standard terms.

7. 7. Specialty chemicals tolling arrangement

   Surabhi, NV Alpha

   Question. What is this chemical tolling opportunity and could you explain it?

   Answer, Kushal Kumar Rana, Director Works. The product falls under the chemical segment. Already a product in the market; mutual agreement with a renowned customer for development and commercial supply. Development has been completed; will be additional to existing portfolio, not currently in portfolio.

8. 8. Ibuprofen global pricing environment

   Subrata Sarkar, Mount Infra

   Question. On the Ibu global environment — IOL is announcing large capex while competitors may be exiting. What is your take on Ibu pricing and margins? Any sharp price increase recently?

   Answer, Kushal Kumar Rana, Director Works. No sharp increase in Ibuprofen pricing currently. Abhay added this is a continuation of long-term strategy, not a response to current situations; should not be read into for pricing implications — it's a targeted strategy fitting the long-term plan.

   Follow-up. Has the Middle East issue impacted Ibu pricing given feedstock has gone up?

   Answer. All that has already been neutralised. Impact was during initial phase of war. Any increase in final prices is matched by raw material price increases too. Neutralised for us.

9. 9. CDMO long-term vision & greenfield capex status

   Maulik, 360 One Capital

   Question. Two questions: (1) From a 3-5 year perspective, what is the vision for the CDMO business? (2) You had acquired ~100 acres of land for greenfield capex — is that now pushed out or coming in simultaneously?

   Answer, Abhay Raj Singh, Sr. VP & Company Secretary. The INR495-500 cr investment announced is separate from the greenfield project at new land. These are not related. Greenfield development is as per initial plan; regulatory approvals being obtained with most already secured and initial base work started; full work begins once all approvals in place. On CDMO vision 3-5 years — will discuss once optimum utilization achieved and we see customer/market response. Too early to discuss beyond 3-4 years for this line.

   Not answered directly.

10. 10. CDMO contract tenure & revenue visibility

    Saumya Raghuvanshi, Nirva Securities

    Question. On the European CDMO facility — can you provide contract tenure and revenue visibility from these anchor customers?

    Answer, Abhay Raj Singh, Sr. VP & Company Secretary. Contract terms similar to existing API product contracts; medium to longer term; finalised with various customers; will update as we progress. Commercialisation at the end of next quarter — much detail will be discussed at that time.

    Follow-up. Could you elaborate on the current order pipeline for the 1,500 mn tablets/yr facility and ramp-up expectations?

    Answer. Customers have development started and regulatory approval initiated since EU-GMP received. Full-capacity utilisation too early to comment. Will progress as development with other anchor customers starts. Optimal utilisation expected in 18-24 months.

    Partly answered.

11. 11. Ibuprofen plant shutdowns and global growth

    Surabhi, NV Alpha

    Question. Follow-up: Back in 2019 when BASF's Ibuprofen plant shut down, demand increased. Is something similar happening — European or other plant shutdowns driving increased Ibu demand?

    Answer, Kushal Kumar Rana, Director Works. No, no information about any other plant shutdown in Europe. Rakesh Mahajan added Ibuprofen global growth rate is 3-4% per year, which also attracts the expansion. Abhay added the expansion is not related to current directions/cycles — this is the company's long-term strategy based on customer engagement and positive feedback globally.

12. 12. Customer-supported capacity & ROCE

    Suhani Singh, ROS Capital

    Question. Two questions: (1) How much of the incremental Ibuprofen capacity is supported by existing customer relationships or ongoing international customer discussions? (2) Across the three ~INR495 crore initiatives, what ROCE or return profile do you expect at steady-state?

    Answer, Rakesh Mahajan, Finance Advisor and Strategic Head. On customer-supported capacity: cannot share the exact percentage, but considering development with new API customers, we are forecasting good volumes. On ROCE: as a company whole, expecting more than ~15% ROCE once all projects are fully implemented.

    Partly answered.

13. 13. Price pass-through and backward integration

    Shaikh Mohd Ayaz, Unknown

    Question. Given the fluctuation in Ibuprofen final prices and raw material costs, with long-term contracts for Ibu and Paracetamol — are we able to pass on these fluctuations to final customers?

    Answer, Abhay Raj Singh, Sr. VP & Company Secretary. Yes, every contract has a price adjustment clause that triggers when prices move beyond a certain level in either direction. Additionally, with Ibu being fully backward integrated, raw material price fluctuation is controlled to the maximum extent. Yes, also backward integrated for Paracetamol. Guidance largely maintained.

14. 14. EBIT, cash flow and growth impact of capex

    Sanjeev Rupera, Unknown

    Question. Three questions: With 30% of investment done and balance in this year out of INR500 crores — (1) Will this impact EBIT this year? (2) Will cash flow increase? (3) What is the expected growth this year?

    Answer, Pardeep Kumar Khanna, Chief Financial Officer. Capex to be incurred across FY27 and FY28. 30% already done; remaining has clear visibility through operations, met from internal accruals. On EBIT — not going to be hit, internal accruals are being used. On top line — assuming the new capex comes into full operations in FY29, that is when 25-30% contribution will come. This year will not be material.

15. 15. Backward/forward integration & capex split

    Rishabh Malik, Artha Capital

    Question. Two questions: (1) You mentioned the CDMO project will use part of the additional Ibuprofen capacity — should we understand the company is fully backward integrated for Ibu and now forward integrating via CDMO formulations? (2) On the multi-year capex — earlier calls mentioned INR1,200-1,400 crores; is the current INR495 crores part of that or fresh, making total INR2,000 crores?

    Answer, Abhay Raj Singh, Sr. VP & Company Secretary. Correct on backward and forward integration; major focus is Europe for anchor customers, not going directly as IOL brand. On capex — these are different. The INR1,200 crores capex is for a greenfield project at another site, around 25-30 km away from the existing site. The two are separate. Products in CDMO relate to existing customers and existing APIs — complete forward integration.

    Follow-up. For the CDMO project, what products/APIs are being developed and which direction is the company taking?

    Answer. As of now, this is relating to existing customers and existing APIs of the company. Whatever products being supplied to existing customers — products and customers are existing. This is how we have structured it.

16. 16. Ibuprofen pricing and margin trajectory

    Rishabh Malik, Artha Capital

    Question. On Ibuprofen pricing — raw material prices had risen and then came down with oil. Have Ibuprofen prices fallen accordingly or are they at elevated levels? Should we expect inflated margins for coming quarters?

    Answer, Abhay Raj Singh, Sr. VP & Company Secretary. Prices of various products went up during the war; since peak, many have softened down but Ibu prices are more or less the same — not much change, hovering at around the same level. Given full backward integration, margin expansion is probable.

17. 17. Future capex pipeline

    Nimish Verma, AES Capital

    Question. Beyond these announced projects, should we expect further capacity additions or investments in API, CDMOs, or specialty chemicals over the next 2-3 years?

    Answer, Abhay Raj Singh, Sr. VP & Company Secretary. Why not? CDMO has just started, yet to be commercialised, so cannot discuss capacity enhancement for CDMO. Ibuprofen expansion you have seen. Over the last two years, on a regular basis, we have been coming up with capacity enhancement for one product or other. Considering capacity utilisation, market responses and future possibilities, we will come up with new products and capacity enhancement both.

Topic by topic, in the order it was spoken

In their words